{
  "meta": {
    "timestamp": "2025-01-06T14:18:40.955535",
    "version": "1.0",
    "type": "search_analysis"
  },
  "companies": [
    {
      "company_name": "Pliant Therapeutics Inc.",
      "symbol": "PLRX",
      "analysis": {
        "historical": {
          "risk_score": 65,
          "key_risks": [
            "Clinical trial risks, including potential failures, safety concerns, and regulatory setbacks",
            "Regulatory challenges and uncertainties in approval pathways",
            "Financial dependence on external funding and investor support",
            "Highly competitive fibrosis treatment market",
            "Stock volatility driven by clinical trial outcomes and market dynamics"
          ],
          "controversies": [
            "Recent stock drop following interim data release from INTEGRIS-PSC Phase 2a trial",
            "Uncertainty around the adaptive Phase 2b/3 BEACON-IPF trial outcomes"
          ],
          "environmental_issues": [],
          "social_issues": [
            "Addressing unmet medical needs in fibrotic diseases, which impact patient quality of life"
          ],
          "governance_issues": [],
          "recommendation": "caution",
          "confidence_score": 80
        },
        "evidence": {
          "sources": [
            {
              "url": "",
              "title": "Pliant Therapeutics Provides Corporate Update and Reports - GlobeNewswire",
              "snippet": "Pliant has initiated BEACON-IPF, an adaptive Phase 2b/3 trial of bexotegrast in IPF. Pliant is conducting a Phase 1 study for its third clinical program, PLN-101095, a small molecule, dual ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Pliant Therapeutics Inc. Pliant Therapeutics Inc. clinical trial failures or delays",
              "retrieved_at": "2025-01-06T21:18:09.788677+00:00",
              "published_date": null,
              "source_hash": "93a16763fae6ea0ce375b712381a5d96"
            },
            {
              "url": "",
              "title": "Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating Bexotegrast ...",
              "snippet": "INTEGRIS-PSC to be featured in an oral presentation on Monday, November 18 SOUTH SAN FRANCISCO, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Pliant Therapeutics Inc. Pliant Therapeutics Inc. clinical trial failures or delays",
              "retrieved_at": "2025-01-06T21:18:09.788769+00:00",
              "published_date": null,
              "source_hash": "099d81b6821ff567d2393e49ff85aa8d"
            },
            {
              "url": "",
              "title": "Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating Bexotegrast ...",
              "snippet": "Pliant has initiated BEACON-IPF, an adaptive Phase 2b/3 trial of bexotegrast in IPF. Pliant is conducting a Phase 1 study for its third clinical program, PLN-101095, a small molecule, dual ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Pliant Therapeutics Inc. Pliant Therapeutics Inc. clinical trial failures or delays",
              "retrieved_at": "2025-01-06T21:18:09.788786+00:00",
              "published_date": null,
              "source_hash": "a2aa8cfac54d5a95b03552f8576f6591"
            },
            {
              "url": "",
              "title": "Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating ... - BioSpace",
              "snippet": "SOUTH SAN FRANCISCO, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced a late-breaking presentation of results from the INTEGRIS-PSC Phase 2a trial of ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Pliant Therapeutics Inc. Pliant Therapeutics Inc. clinical trial failures or delays",
              "retrieved_at": "2025-01-06T21:18:09.788800+00:00",
              "published_date": null,
              "source_hash": "80160d7806bc498cdf8b9fc0c24c5a07"
            },
            {
              "url": "",
              "title": "Clinical Trials - Pliant Therapeutics",
              "snippet": "The INTEGRIS-IPF trial is complete. Based upon the positive data from this trial reported to date, BEACON-IPF has been initiated (scroll up to learn more). Pliant would like to thank our INTEGRIS-IPF clinical sites, investigators and study teams for their assistance in the successful execution of this study.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Pliant Therapeutics Inc. Pliant Therapeutics Inc. clinical trial failures or delays",
              "retrieved_at": "2025-01-06T21:18:09.788811+00:00",
              "published_date": null,
              "source_hash": "e6ec35734705cf498a6a9354aba60879"
            },
            {
              "url": "",
              "title": "Pliant Therapeutics",
              "snippet": "Pliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference . 01-02-2025. Learn More. Pliant Therapeutics to Participate in Upcoming Investor Events ... A late-stage global clinical trial for idiopathic pulmonary \ufb01brosis (IPF). Learn More.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Pliant Therapeutics Inc. Pliant Therapeutics Inc. clinical trial failures or delays",
              "retrieved_at": "2025-01-06T21:18:09.788824+00:00",
              "published_date": null,
              "source_hash": "03e39de754450c8c4d7b50b3833ace16"
            },
            {
              "url": "",
              "title": "Pliant Therapeutics Provides Corporate Update and Reports Third Quarter ...",
              "snippet": "BEACON-IPF Phase 2b trial on track for full enrollment in the first quarter of 2025 with data anticipated in mid-2026. SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage clinical biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Pliant Therapeutics Inc. Pliant Therapeutics Inc. patient safety concerns or ethical controversies",
              "retrieved_at": "2025-01-06T21:18:21.896591+00:00",
              "published_date": null,
              "source_hash": "e50e1397ddb5a2eb0371cfa19ced5f30"
            },
            {
              "url": "",
              "title": "Pliant Therapeutics, Inc. | European Clinical Trials Information Network",
              "snippet": "Pliant Therapeutics is currently engaged in several clinical trials, including a Phase 2 trial for its lead candidate, PLN-74809, which targets idiopathic pulmonary fibrosis (IPF). Overall, Pliant Therapeutics is a dynamic and innovative company that is poised to make a significant impact in the field of fibrosis research.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Pliant Therapeutics Inc. Pliant Therapeutics Inc. clinical trial failures or delays",
              "retrieved_at": "2025-01-06T21:18:09.788847+00:00",
              "published_date": null,
              "source_hash": "2c3178d17d1e472acf5c2223d130f0c2"
            },
            {
              "url": "",
              "title": "Pliant Therapeutics Provides Corporate Update and Reports - GlobeNewswire",
              "snippet": "About Pliant Therapeutics, Inc. Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Pliant Therapeutics Inc. Pliant Therapeutics Inc. clinical trial failures or delays",
              "retrieved_at": "2025-01-06T21:18:09.788858+00:00",
              "published_date": null,
              "source_hash": "800b11f9097712e31ff678b0d7c74edb"
            },
            {
              "url": "",
              "title": "Pliant Therapeutics Provides Corporate Update and Reports ... - BioSpace",
              "snippet": "SOUTH SAN FRANCISCO, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage clinical biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported second quarter 2024 financial results.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Pliant Therapeutics Inc. Pliant Therapeutics Inc. clinical trial failures or delays",
              "retrieved_at": "2025-01-06T21:18:09.788868+00:00",
              "published_date": null,
              "source_hash": "27f880dafc6b158662163588716e9cd2"
            },
            {
              "url": "",
              "title": "Pliant Therapeutics (NASDAQ:PLRX) Stock Price Down 4.9% - Should You Sell?",
              "snippet": "Pliant Therapeutics, Inc. (NASDAQ:PLRX - Get Free Report)'s share price was down 4.9% during trading on Monday . The stock traded as low as $12.59 and last traded at $12.89. Approximately 102,040 shares changed hands during mid-day trading,",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Pliant Therapeutics Inc. Pliant Therapeutics Inc. investor lawsuits or financial disputes",
              "retrieved_at": "2025-01-06T21:18:18.405219+00:00",
              "published_date": "2024-12-30T19:24:00+00:00",
              "source_hash": "158f3b3ebded58dc1d2538e191e1bf83"
            },
            {
              "url": "",
              "title": "Why Is Liver Disease-Focused Pliant Therapeutics Stock Trading Lower Today?",
              "snippet": "Pliant Therapeutics Inc (NASDAQ:PLRX) released 12-week interim data from the 320 mg dose group of INTEGRIS-PSC Phase 2a trial of bexotegrast in patients with primary sclerosing cholangitis (PSC ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Pliant Therapeutics Inc. Pliant Therapeutics Inc. patient safety concerns or ethical controversies",
              "retrieved_at": "2025-01-06T21:18:24.463766+00:00",
              "published_date": "2024-02-05T18:41:00+00:00",
              "source_hash": "af1bee6bdc3000f694ffa8521f648a2f"
            },
            {
              "url": "",
              "title": "Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives $40.50 Consensus Price Target from Analysts",
              "snippet": "Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX - Get Free Report) have been assigned an average rating of \"Buy\" from the eight analysts that are currently covering the stock, Marketbeat.com reports.",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Pliant Therapeutics Inc. Pliant Therapeutics Inc. patient safety concerns or ethical controversies",
              "retrieved_at": "2025-01-06T21:18:24.463681+00:00",
              "published_date": "2024-12-26T05:38:00+00:00",
              "source_hash": "dc427fbe981cc0cc2ff925df020e98d6"
            },
            {
              "url": "",
              "title": "Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results",
              "snippet": "BEACON-IPF Phase 2b trial on track for full enrollment ... Nov. 07, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage clinical biotechnology company and leader ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Pliant Therapeutics Inc. Pliant Therapeutics Inc. clinical trial failures or delays",
              "retrieved_at": "2025-01-06T21:18:12.468884+00:00",
              "published_date": "2024-11-07T21:05:00+00:00",
              "source_hash": "a84f9f8d2533340ba8eacb2a4d19ac18"
            },
            {
              "url": "",
              "title": "Pliant Therapeutics to Participate in Upcoming Investor Events",
              "snippet": "Nov. 21, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq ... Phase 2b/3 trial of bexotegrast in IPF. Pliant is conducting a Phase 1 study for its third clinical program, PLN-101095 ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Pliant Therapeutics Inc. Pliant Therapeutics Inc. clinical trial failures or delays",
              "retrieved_at": "2025-01-06T21:18:12.468893+00:00",
              "published_date": "2024-11-21T08:00:00+00:00",
              "source_hash": "b2054e71a92e282240a0a4fd331081d7"
            },
            {
              "url": "",
              "title": "Pliant Therapeutics Provides Corporate Update and Reports Third Quarter ...",
              "snippet": "About Pliant Therapeutics, Inc. Pliant Therapeutics is a late-stage biopharmaceutical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Pliant Therapeutics Inc. Pliant Therapeutics Inc. investor lawsuits or financial disputes",
              "retrieved_at": "2025-01-06T21:18:15.746240+00:00",
              "published_date": null,
              "source_hash": "c96ba8b91af2453b7bbe703c2b7de9f0"
            },
            {
              "url": "",
              "title": "Press Release - Pliant Therapeutics, Inc.",
              "snippet": "SOUTH SAN FRANCISCO, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported fourth quarter 2022 financial results.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Pliant Therapeutics Inc. Pliant Therapeutics Inc. investor lawsuits or financial disputes",
              "retrieved_at": "2025-01-06T21:18:15.746345+00:00",
              "published_date": null,
              "source_hash": "cc9fef12bbc2354ba2e45bf1ac736147"
            },
            {
              "url": "",
              "title": "Pliant Therapeutics Provides Corporate Update and Reports ... - BioSpace",
              "snippet": "SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage clinical biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported third quarter 2024 financial results.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Pliant Therapeutics Inc. Pliant Therapeutics Inc. investor lawsuits or financial disputes",
              "retrieved_at": "2025-01-06T21:18:15.746360+00:00",
              "published_date": null,
              "source_hash": "7545cbe103fd493cc25b915845fb6b7b"
            },
            {
              "url": "",
              "title": "Pliant Therapeutics Company Profile: Overview and Full News Analysis",
              "snippet": "Pliant Therapeutics, Inc. announced participation in the following December investor events . Members of Pliant's senior management will meet with investors on Tuesday, December 3, 2024 . ... financial circumstances and risk tolerance. Investors and users should consult with licensed legal professionals and investment advisors for any legal ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Pliant Therapeutics Inc. Pliant Therapeutics Inc. investor lawsuits or financial disputes",
              "retrieved_at": "2025-01-06T21:18:15.746372+00:00",
              "published_date": null,
              "source_hash": "7f6dc5592dc2382e0ec5204021e1da98"
            },
            {
              "url": "",
              "title": "PLRX | Pliant Therapeutics Inc. Financial Statements - WSJ",
              "snippet": "Pliant Therapeutics Inc. balance sheet, income statement, cash flow, earnings & estimates, ratio and margins. View PLRX financial statements in full.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Pliant Therapeutics Inc. Pliant Therapeutics Inc. investor lawsuits or financial disputes",
              "retrieved_at": "2025-01-06T21:18:15.746392+00:00",
              "published_date": null,
              "source_hash": "a1ca0ee62eef162e11af74f5571c6a51"
            },
            {
              "url": "",
              "title": "Pliant Therapeutics, Inc. (PLRX) Company Profile & Overview - Stock ...",
              "snippet": "Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. ... Chief Financial Officer: Mike Ouimette J.D. General Counsel and Corporate Secretary: Johannes P. Hull: Chief Business Officer: Dr. Eric A ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Pliant Therapeutics Inc. Pliant Therapeutics Inc. investor lawsuits or financial disputes",
              "retrieved_at": "2025-01-06T21:18:15.746402+00:00",
              "published_date": null,
              "source_hash": "dc363b01556b345832a19c6cab335f25"
            },
            {
              "url": "",
              "title": "Pliant Therapeutics Provides Corporate Update and Reports Third Quarter ...",
              "snippet": "SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Pliant Therapeutics Inc. Pliant Therapeutics Inc. investor lawsuits or financial disputes",
              "retrieved_at": "2025-01-06T21:18:15.746413+00:00",
              "published_date": null,
              "source_hash": "f7c566b7203a4934e7f72b808c4a167d"
            },
            {
              "url": "",
              "title": "Pliant Therapeutics Provides Corporate Update and Reports Third Quarter ...",
              "snippet": "As of September 30, 2020, Pliant had cash, cash equivalents and short-term investments of $294.0 million, compared to $312.5 million as of June 30, 2020. Pliant believes it has sufficient funds to meet its operating and capital requirements into 2023. About Pliant Therapeutics, Inc.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Pliant Therapeutics Inc. Pliant Therapeutics Inc. investor lawsuits or financial disputes",
              "retrieved_at": "2025-01-06T21:18:15.746421+00:00",
              "published_date": null,
              "source_hash": "aa7170e0421b10b0c236bc11ea3619fe"
            },
            {
              "url": "",
              "title": "Pliant Therapeutics, Inc. (PLRX) - Yahoo Finance",
              "snippet": "Find out all the key statistics for Pliant Therapeutics, Inc. (PLRX), including valuation measures, fiscal year financial statistics, trading record, share statistics and more.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Pliant Therapeutics Inc. Pliant Therapeutics Inc. investor lawsuits or financial disputes",
              "retrieved_at": "2025-01-06T21:18:15.746430+00:00",
              "published_date": null,
              "source_hash": "2fdb3f774d91719472e33d0405825e1c"
            },
            {
              "url": "",
              "title": "Pliant Therapeutics Inc Ordinary Shares",
              "snippet": "We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Pliant Therapeutics Inc. Pliant Therapeutics Inc. investor lawsuits or financial disputes",
              "retrieved_at": "2025-01-06T21:18:18.405195+00:00",
              "published_date": "2025-01-03T00:00:00+00:00",
              "source_hash": "199ce427ab7c05af16d225f3c841c713"
            },
            {
              "url": "",
              "title": "Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results",
              "snippet": "Nov. 07, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage ... corporate update and reported third quarter 2024 financial results. \"A highlight to this quarter ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Pliant Therapeutics Inc. Pliant Therapeutics Inc. investor lawsuits or financial disputes",
              "retrieved_at": "2025-01-06T21:18:18.405234+00:00",
              "published_date": "2024-11-07T21:05:00+00:00",
              "source_hash": "0b7e216b04ff5b7716d52eac7700c492"
            },
            {
              "url": "",
              "title": "Pliant Therapeutics to Participate in Upcoming Investor Events",
              "snippet": "Investor Relations and Corporate Communications Pliant Therapeutics, Inc. ir@pliantrx.com Pliant Therapeutics NewsMORE Related Stocks",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Pliant Therapeutics Inc. Pliant Therapeutics Inc. investor lawsuits or financial disputes",
              "retrieved_at": "2025-01-06T21:18:18.405244+00:00",
              "published_date": "2024-11-21T08:00:00+00:00",
              "source_hash": "01771fd891a0df6184539b0844fae51b"
            },
            {
              "url": "",
              "title": "Pliant Therapeutics",
              "snippet": "Pliant is advancing drug development programs targeting a range of fibrotic diseases, with a focus on fibrotic tissue-specific inhibition of integrins and the TGF-\u03b2 pathway. ... Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting\u00ae 2024 . 11-18-2024. Learn More. Careers & Culture. We are passionate about ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Pliant Therapeutics Inc. Pliant Therapeutics Inc. patient safety concerns or ethical controversies",
              "retrieved_at": "2025-01-06T21:18:21.896389+00:00",
              "published_date": null,
              "source_hash": "93c2dcfa212a8d34d63ebefb4641239d"
            },
            {
              "url": "",
              "title": "Developing Novel Treatments - Pliant Therapeutics, Inc.",
              "snippet": "in clinical trials; possible safety and efficacy concerns; regulatory developments; the ability of Pliant to protect its intellectual property rights, and unexpected costs, charges or expenses that reduce cash runway. Pliant's pipeline programs are in various stages of pre-clinical and clinical development, and the process by which",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Pliant Therapeutics Inc. Pliant Therapeutics Inc. patient safety concerns or ethical controversies",
              "retrieved_at": "2025-01-06T21:18:21.896507+00:00",
              "published_date": null,
              "source_hash": "ef695141875f009d20b8b9a0f73544ab"
            },
            {
              "url": "",
              "title": "Clinical Trials - Pliant Therapeutics",
              "snippet": "This study will help establish the bexotegrast safety profile and provide early insights on whether it affects the progression of the disease. Enrollment in INTEGRIS-PSC is complete. Pliant would like to thank our INTEGRIS-PSC clinical sites, investigators and study teams for their assistance in the successful execution of this study.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Pliant Therapeutics Inc. Pliant Therapeutics Inc. patient safety concerns or ethical controversies",
              "retrieved_at": "2025-01-06T21:18:21.896523+00:00",
              "published_date": null,
              "source_hash": "78c196ea7cc3a12492a9b0b97eb7cfce"
            },
            {
              "url": "",
              "title": "About - Pliant Therapeutics",
              "snippet": "Pliant Therapeutics is a clinical-stage biopharmaceutical company leading the way in developing new treatments for fibrotic diseases. As fibrosis is a complex disease, few available treatments for fibrosis exist today. We are committed to advancing novel treatments and prepared to change the fibrosis treatment landscape.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Pliant Therapeutics Inc. Pliant Therapeutics Inc. patient safety concerns or ethical controversies",
              "retrieved_at": "2025-01-06T21:18:21.896534+00:00",
              "published_date": null,
              "source_hash": "08bcf015e2c89d07c4a8f36e4b6bfd83"
            },
            {
              "url": "",
              "title": "Pliant Therapeutics Announces Advancement of Integrin Target in ...",
              "snippet": "Under the terms of the collaboration agreement, Pliant will receive a $4 million milestone payment and research funding to support the initiation of development work on the target. Any new product candidates directed to the target will be subject to milestones and royalties payable to Pliant. About Pliant Therapeutics, Inc.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Pliant Therapeutics Inc. Pliant Therapeutics Inc. patient safety concerns or ethical controversies",
              "retrieved_at": "2025-01-06T21:18:21.896544+00:00",
              "published_date": null,
              "source_hash": "065a4c3521591eedd39e9ade1873e739"
            },
            {
              "url": "",
              "title": "Pliant Therapeutics Announces Positive Safety and Efficacy - GlobeNewswire",
              "snippet": "About Pliant Therapeutics, Inc. Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Pliant Therapeutics Inc. Pliant Therapeutics Inc. patient safety concerns or ethical controversies",
              "retrieved_at": "2025-01-06T21:18:21.896553+00:00",
              "published_date": null,
              "source_hash": "8fb3251155d0f2dc4e0f30c4c92ecb41"
            },
            {
              "url": "",
              "title": "Pliant Therapeutics Poised for Growth: A Strong Buy on Promising Drug ...",
              "snippet": "Pliant Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Its lead product candidate, PLN-74809, is ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Pliant Therapeutics Inc. Pliant Therapeutics Inc. patient safety concerns or ethical controversies",
              "retrieved_at": "2025-01-06T21:18:21.896562+00:00",
              "published_date": null,
              "source_hash": "4af652dba287b7dcdd24106f7646d660"
            },
            {
              "url": "",
              "title": "Pliant Therapeutics - AnnualReports.com",
              "snippet": "Pliant Therapeutics is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases. By harnessing the therapeutic potential of integrin biology and TGF-\u03b2 modulation, Pliant aims to prevent or even reverse fibrosis to address the needs of many patients. ... The company also aims to build a patient ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Pliant Therapeutics Inc. Pliant Therapeutics Inc. patient safety concerns or ethical controversies",
              "retrieved_at": "2025-01-06T21:18:21.896572+00:00",
              "published_date": null,
              "source_hash": "33860f6d33e5751e9abf8d18439ca380"
            },
            {
              "url": "",
              "title": "Pliant Therapeutics Provides Corporate Update and Reports Third Quarter ...",
              "snippet": "Pliant Therapeutics, Inc. Positive interim 12-week safety and efficacy data reported from Phase 2a INTEGRIS-PSC trial in patients with PSC. Positive DSMB safety review recommends INTEGRIS-PSC ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Pliant Therapeutics Inc. Pliant Therapeutics Inc. patient safety concerns or ethical controversies",
              "retrieved_at": "2025-01-06T21:18:21.896582+00:00",
              "published_date": null,
              "source_hash": "3d5e9d6e687a3eced76dcde47f94903e"
            },
            {
              "url": "",
              "title": "Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results",
              "snippet": "Nov. 07, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage ... with the interest from the global physician and patient communities in participating in BEACON-IPF ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Pliant Therapeutics Inc. Pliant Therapeutics Inc. patient safety concerns or ethical controversies",
              "retrieved_at": "2025-01-06T21:18:24.463779+00:00",
              "published_date": "2024-11-07T21:05:00+00:00",
              "source_hash": "60296e00b59202ff3169b728c17e6e10"
            },
            {
              "url": "",
              "title": "Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Average Recommendation of \"Buy\" from Analysts",
              "snippet": "Pliant Therapeutics, Inc. (NASDAQ:PLRX - Get Free Report) has been given an average recommendation of \"Buy\" by the nine analysts that are presently covering the firm, Marketbeat.com reports.",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Pliant Therapeutics Inc. Pliant Therapeutics Inc. patient safety concerns or ethical controversies",
              "retrieved_at": "2025-01-06T21:18:24.463789+00:00",
              "published_date": "2024-11-28T00:00:00+00:00",
              "source_hash": "27ddccfe4cd9bf5bed3626dd700c8027"
            },
            {
              "url": "",
              "title": "Pliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference",
              "snippet": "SOUTH SAN FRANCISCO, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that Bernard Coulie, M.D., Ph.D., President ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Pliant Therapeutics Inc. Pliant Therapeutics Inc. patient safety concerns or ethical controversies",
              "retrieved_at": "2025-01-06T21:18:24.463798+00:00",
              "published_date": "2025-01-02T13:02:00+00:00",
              "source_hash": "a41ee36a4eb9064767485c2c76a3f5af"
            }
          ],
          "queries": [
            {
              "category": "financial_legal",
              "query": "Pliant Therapeutics Inc. clinical trial failures or delays",
              "rationale": "Investigate potential risks associated with clinical trial outcomes and regulatory setbacks",
              "priority": 1
            },
            {
              "category": "financial_legal",
              "query": "Pliant Therapeutics Inc. investor lawsuits or financial disputes",
              "rationale": "Assess financial stability and legal risks related to investor relations",
              "priority": 2
            },
            {
              "category": "ethical_social",
              "query": "Pliant Therapeutics Inc. patient safety concerns or ethical controversies",
              "rationale": "Examine ethical considerations and patient safety issues in clinical trials",
              "priority": 3
            }
          ]
        },
        "categorization": {
          "product_issues": [],
          "conduct_issues": [],
          "tags": [],
          "patterns": {}
        }
      },
      "metadata": {
        "analysis_timestamp": "2025-01-06T14:18:40.955544",
        "data_confidence": 80,
        "pattern_confidence": null
      }
    }
  ]
}